US-China biotech investment security debate intensifies

U.S. officials are tightening scrutiny of foreign investments in the pharmaceutical and biotechnology sectors as China’s role as an R&D partner expands. Executive director John Stanford of Incubate outlined three concern areas – domestic API manufacturing, competitiveness of clinical trials, and the ethics of licensing Chinese innovations – and noted a bipartisan congressional effort to add biotech to the Treasury’s outbound investment‑screening list.

In 2026, licensing agreements between U.S. firms and Chinese biotech companies totaled $43 billion in the first five months, underscoring the depth of cross‑border collaboration. At the same time, the U.S. Department of Defense placed contract‑research organization WuXi AppTec on a list of “Chinese military companies,” a move that could affect its eligibility for future U.S. government contracts under the BIOSECURE Act. WuXi AppTec disputes the designation and is taking steps to mitigate impact, including selling certain U.S. and U.K. assets.

China’s biotech capabilities were highlighted at ASCO 2026, where Akeso’s ivonescimab, the first therapy derived solely from a Chinese clinical trial, earned a plenary session presentation. Analysts say China has moved beyond generic manufacturing to develop globally competitive advanced therapies, raising both economic opportunities and national‑security concerns for the United States.